Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 46: 560-f-576-f, 2000;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Apple, F. S.
Right arrow Articles by Murakami, M. M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Apple, F. S.
Right arrow Articles by Murakami, M. M.
Related Collections
Right arrow Proteomics and Protein Markers
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 2000;46:560-576.)
© 2000 American Association for Clinical Chemistry, Inc.

Technical Briefs

Preliminary Evaluation of the Vitros ECi Cardiac Troponin I Assay

Fred S. Apple1,a, Brenda Koplen1 and MaryAnn M. Murakami1

1 Hennepin County Medical Center, Clinical Laboratories MC 812, 701 Park Ave., Minneapolis, MN 55425.
a Author for correspondence: fax 612-904-4229, e-mail fred.apple@co.hennepin.mn.us)

The recently published standards of practice for the use of cardiac marker testing for ruling in and ruling out acute myocardial infarction (AMI) recommend the implementation of cardiac troponin I (cTnI) or T (cTnT) as appropriate markers (1). The purpose of this preliminary study was to analytically and clinically evaluate the Ortho-Clinical Diagnostics (Rochester, NY) Vitros Troponin I immunodiagnostic assay.

The Vitros ECi system uses reagents containing biotinylated monoclonal anti-cTnI antibody and goat polyclonal anti-cTnI antibody labeled with horseradish peroxidase. After an 8-min incubation for reagents and sample in a well precoated with streptavidin, the well is washed and a signal reagent containing horseradish peroxidase substrates is added to detect peroxidase bound to the well by utilizing an enhanced chemiluminescence reaction (2).

The imprecision (as the CV, %) within the same calibration performed according to NCCLS guidelines (3) showed the following results: between-run (n = 80) means over 31 days on 20 occasions were 0.347 µg/L (10%), 0.768 µg/L (5.9%), 4.10 µg/L . . . [Full Text of this Article]


Acknowledgments


References






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Association for Clinical Chemistry.